AG chemotherapy

DRUG3 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Sir Run Run Shaw Hospital, Zhejiang Cancer Hospital

Conditions

Advanced Pancreatic Ductal AdenocarcinomaNon-Resectable Pancreas CarcinomaPancreatic Cancer

Phase 2

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

RecruitingNCT06404840

Tianjin Medical University Cancer Institute and HospitalPancreatic Cancer

Start: 2022-05-06End: 2026-05-31Target: 30Updated: 2024-05-08

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

RecruitingNCT06825546

Sir Run Run Shaw HospitalAdvanced Pancreatic Ductal Adenocarcinoma

Start: 2025-04-01End: 2027-10-01Target: 70Updated: 2025-06-27

Phase 3

Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

RecruitingNCT07235930

Zhejiang Cancer HospitalNon-Resectable Pancreas Carcinoma

Start: 2025-11-15End: 2029-07-01Target: 292Updated: 2025-11-19